See more : E-Qure Corp. (EQUR) Income Statement Analysis – Financial Results
Complete financial analysis of Ayala Pharmaceuticals, Inc. (AYLA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ayala Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Harbor Custom Development, Inc. (HCDIP) Income Statement Analysis – Financial Results
- Quhuo Limited (9J4.F) Income Statement Analysis – Financial Results
- Atrium Mortgage Investment Corporation (AI.TO) Income Statement Analysis – Financial Results
- China Hi-Tech Group Co., Ltd. (600730.SS) Income Statement Analysis – Financial Results
- Goldplat PLC (GDP.L) Income Statement Analysis – Financial Results
Ayala Pharmaceuticals, Inc. (AYLA)
About Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 692.00K | 0.00 | 3.71M | 2.33M | 0.00 |
| Cost of Revenue | 602.00K | 3.51M | 3.71M | 1.29M | 0.00 |
| Gross Profit | 90.00K | -3.51M | 0.00 | 1.05M | 0.00 |
| Gross Profit Ratio | 13.01% | 0.00% | 0.00% | 44.94% | 0.00% |
| Research & Development | 27.85M | 29.94M | 22.41M | 14.42M | 5.74M |
| General & Administrative | 9.74M | 9.28M | 7.37M | 4.34M | 3.29M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.74M | 9.28M | 7.37M | 4.34M | 3.29M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 37.59M | 39.22M | 29.78M | 18.76M | 9.04M |
| Cost & Expenses | 38.20M | 42.72M | 33.49M | 20.05M | 9.04M |
| Interest Income | 0.00 | 0.00 | 56.00K | 225.00K | 448.00K |
| Interest Expense | -74.00K | -1.55M | 56.00K | 225.00K | 0.00 |
| Depreciation & Amortization | 162.00K | 168.00K | 182.00K | 150.00K | 49.00K |
| EBITDA | -37.50M | -40.86M | -29.48M | -17.11M | -8.54M |
| EBITDA Ratio | -5,419.51% | 0.00% | -795.12% | -733.12% | 0.00% |
| Operating Income | -37.50M | -41.03M | -29.78M | -17.71M | -9.04M |
| Operating Income Ratio | -5,419.51% | 0.00% | -803.05% | -758.83% | 0.00% |
| Total Other Income/Expenses | 74.00K | 3.25M | 56.00K | 225.00K | 448.00K |
| Income Before Tax | -37.43M | -39.48M | -29.72M | -17.49M | -8.59M |
| Income Before Tax Ratio | -5,408.82% | 0.00% | -801.54% | -749.19% | 0.00% |
| Income Tax Expense | 584.00K | -776.00K | 425.00K | 306.00K | 286.00K |
| Net Income | -38.01M | -38.70M | -30.15M | -17.79M | -8.87M |
| Net Income Ratio | -5,493.21% | 0.00% | -813.00% | -762.30% | 0.00% |
| EPS | -2.46 | -3.92 | -3.06 | -2.07 | -1.31 |
| EPS Diluted | -2.46 | -3.92 | -3.06 | -2.07 | -1.31 |
| Weighted Avg Shares Out | 15.45M | 9.86M | 9.86M | 8.58M | 6.77M |
| Weighted Avg Shares Out (Dil) | 15.45M | 9.86M | 9.86M | 8.58M | 6.77M |
AYLA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Ayala Pharmaceuticals, Inc. Is Fair to Shareholders
Ayala Pharmaceuticals, Inc. (AYLA) Upgraded to Buy: Here's Why
Ayala Pharmaceuticals Selected to Present Efficacy and Tolerability Data on AL102 in Desmoid Tumors at the European Society for Medical Oncology (ESMO) 2022 Congress
7 Short-Squeeze Stocks to Put on Your Must-Watch List
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q2 Loss, Misses Revenue Estimates
Penny Stocks To Buy Now? 4 To Watch After LTRPB Stock Jumped Over 372%
Ayala Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q1 Loss, Misses Revenue Estimates
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q4 Loss, Tops Revenue Estimates
Ayala Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports